Shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $16.50.

A number of equities research analysts recently commented on the company. Wedbush reissued an “outperform” rating and issued a $19.00 price target on shares of Entasis Therapeutics in a research report on Tuesday, April 2nd. Zacks Investment Research raised Entasis Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Thursday, April 4th.

Shares of ETTX traded down $0.09 during trading hours on Thursday, reaching $6.70. The stock had a trading volume of 10,000 shares, compared to its average volume of 11,971. Entasis Therapeutics has a 12 month low of $3.97 and a 12 month high of $13.70. The stock has a market cap of $86.00 million and a P/E ratio of -0.54.

Entasis Therapeutics (NASDAQ:ETTX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.24). Analysts anticipate that Entasis Therapeutics will post -3.85 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETTX. FNY Investment Advisers LLC raised its position in Entasis Therapeutics by 13,801.0% in the 4th quarter. FNY Investment Advisers LLC now owns 13,901 shares of the company’s stock valued at $56,000 after buying an additional 13,801 shares during the last quarter. BlackRock Inc. purchased a new stake in Entasis Therapeutics in the 4th quarter valued at $56,000. Janney Montgomery Scott LLC purchased a new stake in Entasis Therapeutics in the 4th quarter valued at $169,000. Finally, Credit Suisse AG purchased a new stake in Entasis Therapeutics in the 3rd quarter valued at $757,000. 65.57% of the stock is owned by institutional investors and hedge funds.

Entasis Therapeutics Company Profile

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

See Also: Economic Reports

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.